Following on from information provided to NICE by the company, the appraisal of Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417] has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 10710 |
Email enquiries
- If you have any queries please email topic.selection@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 August 2024 | Discontinued. Following on from information provided to NICE by the company, the appraisal of Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417] has been discontinued. |
| 20 March 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual